Daiichi Sankyo's Anti-clotting Drug Effient Draws Muted Acceptance In U.S., But Cost Analysis Shows Effient Cheaper Than Plavix
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The delayed U.S. launch of Daiichi Sankyo's and Eli Lilly's anti-blood clotting drug Effient (prasugrel) is drawing a muted initial U.S. practitioner acceptance, yet it could become more than a formidable rival of competing medicine, Plavix in the long run, company spokespersons and analysts told PharmAsia News.